Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Gains from Investment Securities: 2013-2024

Historic Gains from Investment Securities for Zevra Therapeutics (ZVRA) over the last 12 years, with Dec 2024 value amounting to $6.0 million.

  • Zevra Therapeutics' Gains from Investment Securities rose 57.43% to $65.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $222.5 million, marking a year-over-year increase of 277.07%. This contributed to the annual value of $6.0 million for FY2024, which is 25.82% down from last year.
  • According to the latest figures from FY2024, Zevra Therapeutics' Gains from Investment Securities is $6.0 million, which was down 25.82% from $8.0 million recorded in FY2023.
  • Zevra Therapeutics' Gains from Investment Securities' 5-year high stood at $8.0 million during FY2023, with a 5-year trough of $355,785 in FY2020.
  • In the last 3 years, Zevra Therapeutics' Gains from Investment Securities had a median value of $6.0 million in 2024 and averaged $5.5 million.
  • In the last 5 years, Zevra Therapeutics' Gains from Investment Securities tumbled by 93.15% in 2020 and then spiked by 258.05% in 2021.
  • Over the past 5 years, Zevra Therapeutics' Gains from Investment Securities (Yearly) stood at $355,785 in 2020, then soared by 258.05% to $1.3 million in 2021, then spiked by 92.83% to $2.5 million in 2022, then soared by 226.62% to $8.0 million in 2023, then declined by 25.82% to $6.0 million in 2024.